Pharmacokinetics, Tolerability, Safety, and Immunogenicity of LY01008 and Bevacizumab (Avastin (R)) in Healthy Chinese Subjects

Xie, LJ; Zhu, Y; Liang, ZJ; Zhao, YQ; Zhou, SF; Chen, J; Zhang, HW; Ding, SJ; Wang, L; Shao, F

Wang, L; Shao, F (通讯作者)，Nanjing Med Univ, Affiliated Hosp 1, Phase Clin Trial Unit 1, 300 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China.;Shao, F (通讯作者)，Nanjing Med Univ, Sch Pharm Coll, Dept Clin Pharmacol, Nanjing 211166, Jiangsu, Peoples R China.

EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2022; 47 (3): 309

Abstract

Background and Objective LY01008 had been identified as being highly similar to the bevacizumab reference product in the pharmacy and pharmacology ter......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索